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To the Editor,
Hematopoietic stem cell transplantation (HSCT) with non-
myeloablative regimens has become more feasible and it is currently 
performed more frequently in adult patients with sickle cell disease 
(SCD) [1]. Hsieh [1] reported successful outcomes for adults with 
a regimen of alemtuzumab and low-dose total body irradiation 
(TBI) in transplants from human leukocyte antigen (HLA)-matched 
sibling donors. We have obtained sustained full chimerism in 13 
adults with protocols including antithymocyte globulin (ATG) 
and busulfan without any significant complications (unpublished 
data). For unrelated donors, the ongoing STRIDE study uses 
conditioning regimens containing ATG, fludarabine, and busulfan. 
Bolaños-Meade et al. [2] achieved a cure with HLA-haploidentical 
transplants performed with ATG, fludarabine, and low-dose TBI. 
Given that these protocols may allow assisted or spontaneous 
pregnancies, fertility issues need to be examined [3] because the 
patient may think that he/she is completely cured after allogeneic 
transplantation and that he/she no longer carries the hemoglobin 
S (Hb S) gene. This erroneous belief may lead to the delivery of a 
homozygous Hb SS infant if the partner has a high risk of being 
a Hb S gene carrier when marriages of close relatives occur, as in 
some populations like Eti-Turks.
SCD is the most common hereditary disease worldwide. The impaired 
microcirculation caused by rigid erythrocytes leads to considerable 
mortality and severe morbidity if not managed appropriately [4]. 
The only proven curative therapy is HSCT. However, this treatment 
carries high risk for infertility as a major complication for young 
patients [5]. Factors predisposing to infertility in these patients 
include delayed puberty, priapism, and gonadal dysfunction with 
increased abnormal spermatozoa, seminal vesicle and prostate 
gland abnormalities, decreased ejaculate volume, lower testosterone 
levels, and low sperm counts in males [6,7,8]. Conditioning regimens 
including alemtuzumab and low-dose TBI are reported not to 
irreparably impair spermatogenesis, although there are insufficient 
data about non-myeloablative conditioning including ATG and 
busulfan [9].
When young SCD patients want to marry after full recovery 
with transplantation, some of them tend to hide their disease 
intentionally or due to a lack of awareness. A complete blood count 
and hemoglobin electrophoresis test as part of the screening done 
before marriage may give normal results. Consequently, affected 
germ cells may be overlooked. This may result in giving birth to 
affected children. The transplant team is responsible for providing 
sufficient information about these issues.
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To the Editor, 
Depression is determined in 15%-25% of patients with cancer 
and it is accepted as a comorbid problem with poor prognosis. 
The quality of life of these patients is determined to be poor 
[1,2]. We aimed to study the quality of life of patients using new 
forms of imatinib, dasatinib, or nilotinib.
We analyzed 56 chronic myeloid leukemia patients followed in 
the İzmir Tepecik Training and Research Hospital Department 
of Hematology. Patients were followed from 2005 to 2015. We 
included patients who were >18 years of age, BCR-ABL-positive 
based on polymerase chain reaction results, using first- or 
second-generation tyrosine kinase inhibitors (TKIs) in the last 6 
months, and in the chronic phase of the disease. 
The Turkish version of the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire-C30 
(EORTC QLQ-C30) [3], the Turkish version of the Hospital Anxiety 
and Depression Scale [4], and the General Health Questionnaire 
[5] were administered to patients one-on-one. The study 
received approval from the ethics committee. 
The demographic data and laboratory values are provided in 
Table 1. 
In our study, we found no statistical significance between first- 
and second-generation TKIs. We also compared dasatinib and 
nilotinib as subgroups of the second generation and we found 
statistical significance for dasatinib against nilotinib for general 
life quality, emotional and cognitive functions, and fatigue 
parameters. 
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